Is it safer CARs that we need, or safer rules of the road?

Molecular Therapy

Volumn 18, Issue 10, 2010, Pages 1742-1743

  Junghans, Richard P ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; CELL DEATH; CLINICAL PROTOCOL; CYTOTOXICITY; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; LIVER TOXICITY; LYMPHOCYTE DEPLETION; MOLECULAR THERAPY; REGULATORY T LYMPHOCYTE; SAFETY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 77957556185     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.162     Document Type: Letter

References (9)

1. Brentjens, R, Yeh, R, Bernal, Y, Riviere, I and Sadelain M (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18: 666-668.
2. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
3. Lamers, CHJ, Sleijfer, S, Vulto, AG, Kruit, WHJ, Kliffen, M, Debets, R et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-e22.
4. Heslop, HE (2010). Safer CARs. Mol Ther 18: 661-662.
5. Eshhar, Z (2008). The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 181: 329-342.
6. Dudley, ME, Wunderlich, JR, Yang, JC, Sherry, RM, Topalian, SL, Restifo, NP et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
7. Mackinnon, S, Papadopoulos, EB, Carabasi, MH, Reich, L, Collins, NH, Boulad, F et al. (1995). Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86: 1261-1268.
8. Sykes, M and Spitzer, TR (2002). Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat Res 110: 79?99.
9. Junghans, RP (2010). Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies. J Transl Med 8:55.